Literature DB >> 32891958

Measles immunity and immunosuppression.

Diane E Griffin1.   

Abstract

Effects of measles on the immune system are only partially understood. Lymphoid tissue is a primary site of measles virus (MeV) replication where CD150 is the receptor for infection of both B and T cells. Lymphocyte depletion occurs during the acute phase of infection, but initiation of the adaptive immune response leads to extensive lymphocyte proliferation, production of MeV-specific antibody and T cells, the rash and clearance of infectious virus. Viral RNA persists in lymphoid tissue accompanied by ongoing germinal center proliferation, production of antibody-secreting cells, functionally distinct populations of T cells and antibody avidity maturation to establish life-long immunity. However, at the same time diversity of pre-existing antibodies and numbers of memory and naive B cells are reduced and susceptibility to other infections is increased.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID: 32891958      PMCID: PMC7994291          DOI: 10.1016/j.coviro.2020.08.002

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  64 in total

1.  Silent casualties from the measles outbreak in South Africa.

Authors:  Christine Albertyn; Helen van der Plas; Diana Hardie; Sally Candy; Tamiwe Tomoka; Edward B Leepan; Jeannine M Heckmann
Journal:  S Afr Med J       Date:  2011-05

2.  Proteolytic cleavage of the fusion protein but not membrane fusion is required for measles virus-induced immunosuppression in vitro.

Authors:  A Weidmann; A Maisner; W Garten; M Seufert; V ter Meulen; S Schneider-Schaulies
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition.

Authors:  C Erlenhoefer; W J Wurzer; S Löffler; S Schneider-Schaulies; V ter Meulen; J Schneider-Schaulies
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Plasma Cytokines and Chemokines in Zambian Children With Measles: Innate Responses and Association With HIV-1 Coinfection and In-Hospital Mortality.

Authors:  Wen-Hsuan W Lin; Ashley N Nelson; Judith J Ryon; William J Moss; Diane E Griffin
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

5.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration.

Authors:  Cristian Condack; Jean-Charles Grivel; Patricia Devaux; Leonid Margolis; Roberto Cattaneo
Journal:  J Infect Dis       Date:  2007-06-29       Impact factor: 5.226

7.  Slow clearance of measles virus RNA after acute infection.

Authors:  Michaela A Riddell; William J Moss; Debra Hauer; Mwaka Monze; Diane E Griffin
Journal:  J Clin Virol       Date:  2007-07-10       Impact factor: 3.168

8.  Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles.

Authors:  Velislava N Petrova; Bevan Sawatsky; Alvin X Han; Brigitta M Laksono; Lisa Walz; Edyth Parker; Kathrin Pieper; Carl A Anderson; Rory D de Vries; Antonio Lanzavecchia; Paul Kellam; Veronika von Messling; Rik L de Swart; Colin A Russell
Journal:  Sci Immunol       Date:  2019-11-01

9.  Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques.

Authors:  Rik L de Swart; Martin Ludlow; Lot de Witte; Yusuke Yanagi; Geert van Amerongen; Stephen McQuaid; Selma Yüksel; Teunis B H Geijtenbeek; W Paul Duprex; Albert D M E Osterhaus
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

Review 10.  Responses to Microbial Challenges by SLAMF Receptors.

Authors:  Boaz Job van Driel; Gongxian Liao; Pablo Engel; Cox Terhorst
Journal:  Front Immunol       Date:  2016-01-20       Impact factor: 7.561

View more
  6 in total

1.  Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection.

Authors:  Olivier Reynard; Claudia Gonzalez; Claire Dumont; Mathieu Iampietro; Marion Ferren; Sandrine Le Guellec; Laurie Lajoie; Cyrille Mathieu; Gabrielle Carpentier; Georges Roseau; Francesca Bovier; Yun Zhu; Deborah Le Pennec; Jerome Montharu; Amin Addetia; Alexander Greninger; Christopher Alabi; Anne Moscona; Laurent Vecellio; Matteo Porotto; Branka Horvat
Journal:  Res Sq       Date:  2022-06-01

2.  Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History.

Authors:  Katalin Böröcz; Senka Samardžić; Ines Drenjančević; Ákos Markovics; Tímea Berki; Péter Németh
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

3.  Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant: A case report.

Authors:  Qing-Hua Yang; Xiao-Peng Ma; Dong-Ling Dai; Da-Ming Bai; Yu Zou; Si-Xi Liu; Jian-Ming Song
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

Review 4.  Current view on novel vaccine technologies to combat human infectious diseases.

Authors:  Zrinka Matić; Maja Šantak
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-10       Impact factor: 4.813

5.  Are previous viral infections important on the COVID-19 outcomes?

Authors:  Jesus Torres-Flores; Nora A Fierro
Journal:  Ann Hepatol       Date:  2021 Nov-Dec       Impact factor: 2.400

6.  Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein.

Authors:  Francesca T Bovier; Ksenia Rybkina; Sudipta Biswas; Olivia Harder; Tara C Marcink; Stefan Niewiesk; Anne Moscona; Christopher A Alabi; Matteo Porotto
Journal:  ACS Nano       Date:  2021-07-22       Impact factor: 18.027

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.